

Fig. 2 Schematic presentation of subsegments of the caudate lobe




Table 1 Origins of tumor-feeding arteries of 88 HCCs in the caudate lobe

Origin	No. (%)	
R ₁	11 (9.5)	32 (27.6%)
R ₂	21 (18.1)	
L ₁	9 (7.8)	24 (20.7%)
L ₂	15 (12.9)	
A	24 (20.7)	
P	25 (21.6)	
M	7 (6.0)	
Ph	1 (0.9)	
Ch	0 (0)	
Ex	3 (2.6)	
Total	116 (1.3 ± 0.5 arteries/tumor)	

Mean tumor diameter 21.4 ± 11.0 mm [range 8–62]

Origins of the Caudate Arteries Supplying HCCs in the PC

Our findings are listed in Table 3. There were 38 tumors with a mean diameter of 20.2 ± 9.3 mm (range 8–47) in the PC. Twenty-nine tumors (76.3%) were supplied by a single feeding artery. Among these, 20 tumors were supplied by the caudate artery derived from the right hepatic arterial system (R₁ [n = 4], R₂ [n = 7], A [n = 3], P [n = 6]). Nine were supplied by the caudate artery derived from the left hepatic arterial system (L₁ [n = 1], L₂ [n = 5], M [n = 3]). Seven tumors (18.4%) had two feeding arteries. Among these, three tumors were supplied by feeding arteries derived from the right (A [n = 1], P

Table 2 Feeding arteries of 36 HCCs in the SP

No. of feeders	No. of tumors (%)	Site	Origin	Tumor	
1	25 (69.4)	R	R ₁	2	
			R ₂	7	
			A	2	
			P	4	
			L	L ₁	3
			L ₂	4	
		L	M	2	
			Ex	Ex ^a	1
			R + L	R ₁ , L ₁	1
				R ₁ , L ₂	1
				R ₂ , L ₁	1
A, L ₁	1				
2	11 (30.6)	R + L	A, L ₂	2	
			A, M	1	
			P, L ₂	1	
			R × 2	A × 2	1
			L + Ex	L ₂ , Ex ^b	1
			M, Ex ^a	1	

Mean tumor diameter 22.3 ± 11.9 mm [range 8–62]. The ratio of R:L = 25:19

^a Arising from the right inferior phrenic artery

^b Arising from the accessory left gastric artery

[n = 2]) and the left hepatic arterial system (L₁ [n = 2], L₂ [n = 1]), respectively. Four tumors were supplied by two feeding arteries derived from the right hepatic arterial system (R₂ and P [n = 1], A × 2 [n = 1], A and P




Fig. 3 A 45-year-old woman with HCC in the SP. **A** Common hepatic arteriogram showed that the caudate artery derived from the right hepatic artery proximal to the middle hepatic artery (*arrow*).

B The caudate artery was selected, and TACE was performed. **C** CT obtained 1 week after TACE showed dense iodized oil accumulation in HCC in the SP




Fig. 4 A 73-year-old woman with HCC in the SP. **A** Common hepatic arteriogram showed tumor stains in the caudate lobe (*arrow*) and in the right lobe near the previously embolized tumor (*arrowhead*). **B** Arteriogram of the anterior segmental artery of the right hepatic artery showed tumor stains. The arrow shows the caudate artery. **C** The caudate artery was selected, and TACE was performed.

Subsequently, the tumor in the right lobe was also embolized (not shown). **D** Arteriogram of the medial segmental artery showed a residual tumor stain of HCC in the caudate lobe (*arrows*). The *arrowhead* shows the caudate artery. **E** The caudate artery was selected, and TACE was performed. **F** CT obtained 1 week after TACE showed dense iodized oil accumulation in HCC in the SP




Fig. 5 A 78-year-old man with HCC in the SP. **A** Common hepatic arteriogram showed that the caudate artery derived from the proximal right hepatic artery (*arrow*). Another tumor stain in the right lobe of the liver was also seen (*arrowhead*). **B** Selective arteriogram of the caudate artery showed two tumor stains. This vessel was embolized. Subsequently, the tumor in the right lobe was also embolized (not shown). **C** CT obtained 1 week after TACE showed that iodized oil was densely accumulated in the tumor in the SP, but a tumor portion without iodized oil accumulation was seen (*arrows*). Iodized oil was

also densely accumulated other tumors in the right lobe of the liver. **D** Arteriogram of the left hepatic artery obtained 4 months after initial TACE showed that the caudate artery derived from the distal left hepatic artery (*arrow*), and a residual tumor stain (*arrowhead*) was seen. The falciform artery was also seen (*asterisk*). **E** The caudate artery was selected and embolized. **F** CT obtained 1 week after second TACE showed dense iodized oil accumulation in the entire tumor

[$n = 2$]). The remaining two tumors (5.3%), which were 14 and 23 mm in diameter, respectively, were supplied by three feeding arteries derived from the right hepatic arterial system at R_1 , A, and P and R_2 , A, and P, respectively (Fig. 6). In total, there were 49 tumor-feeding caudate arteries. Thirty-seven tumor-feeding caudate arteries arose from the right hepatic arterial system, and 12 arose from the left hepatic arterial system.

Origins of the Caudate Arteries Supplying HCCs in the CP

Our findings are listed in Table 4. There were 14 tumors with a mean diameter of 21.8 ± 12.9 mm (range 12–49) in the CP. Nine tumors (64.3%) were supplied by a single feeding artery. Among these, seven tumors were supplied by a feeding artery derived from the right hepatic arterial system (R_1 [$n = 1$], A [$n = 3$], P [$n = 3$]) (Fig. 7); one

was supplied by the caudate artery derived from M; and one was supplied by the caudate artery derived from Ph. Four tumors were supplied by two feeding arteries derived from the right hepatic arterial system (R_1 and R_2 [$n = 1$], R_2 and A [$n = 1$], A \times 2 [$n = 1$], P \times 2 [$n = 1$]). The remaining tumor (7.1%), which was 13 mm in diameter, was supplied by three feeding arteries derived from the right hepatic arterial system at R_2 , P, and P, respectively. In total, there were 20 tumor-feeding caudate arteries. Eighteen tumor-feeding arteries arose from the right hepatic arterial system; one arose from the middle hepatic artery; and one arose from the proper hepatic artery.

Discussion

A cadaver dissection study by Mizumoto et al. [10] reported that the caudate arteries arose from the posterior

Table 3 Feeding arteries of 38 HCCs in the PC

No. of feeders	No. of tumors	Site	Origin	Tumor
1	29 (76.3%)	R	R ₁	4
			R ₂	7
			A	3
			P	6
		L	L ₁	1
			L ₂	5
			M	3
2	7 (18.4%)	R + L	A, L ₁	1
			P, L ₁	1
			P, L ₂	1
		R × 2	R ₂ , P	1
			A × 2	1
			A, P	2
3	2 (5.3%)	R × 3	R ₁ , A, P	1
			R ₂ , A, P	1

Mean tumor diameter 20.2 ± 9.3 mm [range 8–47]. The ratio of R:L = 37:12

segmental artery of the right hepatic artery and the left hepatic artery in 32.1% of 106 cadavers; from the posterior segmental artery of the right hepatic artery and the middle hepatic artery in 26.4% of cadavers; and from these three arteries in 20.8% of cadavers. In another cadaver study by Suzuki [11], the right-side caudate artery arose from the posterior segmental artery of the right hepatic artery in 89.7% of cadavers, and only 9.3% arose from the right hepatic artery. However, in previous angiographic observations, the most common origin of the caudate artery was the right hepatic artery [7–9]. In addition, the incidences of the caudate artery derived from the left hepatic artery and the posterior segmental artery of the right hepatic artery were low compared with those reported in dissection studies [7]. The cause of this discrepancy between dissection study and angiographic study is speculated as follows: First, the caudate artery derived from the right hepatic artery can easily be identified on arteriogram because there is less superimposition of the hepatic branches. Second, because the left hepatic lobe has a limited depth, identification of the caudate artery is difficult even on stereo angiogram [7]. Finally, the caudate artery derived from the posterior segmental artery is frequently difficult to recognize as the caudate artery on arteriogram because it mimics the branches of the posterior segmental artery of the right hepatic artery [7]. Therefore, there is a significant limitation in nonselective angiographic evaluations of the caudate arteries. Moreover, some small caudate branches derived from the proximal portion of the hepatic artery might be killed during preparation in dissection studies.

With advances in catheter technology, superselective catheterization and chemoembolization at the most distal level of the subsegmental artery of the liver have become possible [14, 15], even through the caudate arteries [9, 12, 16]. Iodized oil injected during the TACE procedure can clearly indicate the vascular territory of the embolized branch on CT. In the present study, we could easily recognize that the embolized branch was the caudate artery when iodized oil was retained in the caudate lobe, including the tumor, on CT obtained 1 week after TACE. This evaluation method facilitates precise identification of the caudate artery, although this artery frequently mimics other hepatic branches on arteriogram alone.

In the present study, the most frequent origin of the tumor-feeding caudate artery was the right hepatic artery, followed with almost equal frequency by the left hepatic artery, the anterior segmental artery, and the posterior segmental artery of the right hepatic artery. Our results suggest that the caudate artery actually can be identified from the right hepatic artery most frequently and not just because it can easily be identified on arteriogram due to less superimposition of the hepatic branches. Among the caudate arteries derived from the right and left hepatic arteries, it dominantly arose from the distal portion (R₂ and L₂). In addition, the ratio of the caudate artery origin of the right hepatic arterial system to the left hepatic arterial system was 2.6:1. However, HCCs in the CP were fewer than those in the SP and the PC in the present study. If our cohort had included more tumors in the CP, the number of caudate arteries derived from the right hepatic arterial system might have increased.

The origins of the tumor-feeding caudate arteries may differ among the three subsegment locations of HCC [8, 9, 12]. In the present study, HCCs located in the SP were fed from the caudate arteries derived from the right and left hepatic arterial systems (the ratio of right to left = 3:2). In addition, the extrahepatic vessels infrequently feed HCCs in the SP, in particular those located at the liver surface. HCCs in the PC were also fed by the caudate arteries derived from the right and left hepatic arterial systems, with a lower frequency arising from the left hepatic arterial supply (the ratio of right to left = 3:1). Almost all HCCs in the CP were dominantly fed by the caudate artery derived from the right hepatic arterial system, mainly arising from the anterior or posterior segmental artery of the right hepatic artery. This tendency may be helpful to identify the tumor-feeding caudate artery according to the tumor location. Yoon et al. [9] also reported a similar tendency, although the incidences of blood supply to HCCs in the PC from the left hepatic arterial system were low compared with those in our series. We selected patients with HCCs in the caudate lobe that had not previously been treated. However, 62% of patients had previously undergone TACE for other HCCs before detection of HCCs in the




Fig. 6 A 75-year-old woman with HCC in the PC. **A** Celiac arteriogram showed three caudate arteries (*arrows*). **B** The caudate artery derived from the distal portion of the right hepatic artery was selected and arteriogram showed a tumor stain (*arrow*). TACE was performed at this point. **C** The caudate artery deriving from the posterior segmental artery of the right hepatic artery was selected, and the arteriogram also showed a tumor stain (*arrow*). TACE was

performed. **D** The caudate artery deriving from the anterior segmental artery of the right hepatic artery was selected, and TACE was performed. **E** Spot radiograph obtained during TACE showed dense iodized oil accumulation in the tumor. **F** CT obtained 1 week after TACE showed dense iodized oil accumulation in HCC and the caudate lobe

Table 4 Feeding arteries of 14 HCCs in the CP

No. of feeders	No. of tumors (%)	Site	Origin	Tumor
1	9 (64.3)	R	R ₁	1
			A	3
			P	3
			M	1
			Ph	1
2	4 (28.6)	R × 2	R ₁ , R ₂	1
			R ₂ , A	1
			A × 2	1
			P × 2	1
				1
3	1 (7.1)	R × 3	R ₂ , P × 2	1

Mean tumor diameter 21.8 ± 12.9 mm [range 12–49]

caudate lobe. Previous TACE through the neighboring branches of the caudate lobe might have changed the vascular territories of the caudate arteries.

There are several limitations in the present study. First, we did not evaluate the caudate arteries that were identified on arteriogram, but that did not supply the tumor, because we could not definitely confirm whether these vessels exactly supplied the caudate lobe on angiographic findings alone. Therefore, our study did not analyze the origins of all of the caudate arteries, and this might strongly influence the number and origin of the caudate arteries detected. Three-dimensional CT during hepatic arteriography, using a multidetector-row CT, may provide sufficient information about the caudate arteries, including those that do not supply the tumor. Second, the number of tumor-feeding caudate arteries might easily change according to the tumor size. In large tumors, small caudate branches may become hypertrophied enough to be depicted on arteriogram, and parasitization of the extrahepatic collateral vessels may also become apparent. Finally, there was a possibility of missing small tumor-feeding caudate branches, although iodized oil was accumulated in all tumors throughout the




Fig. 7 A 64 year-old man with HCC in the CP. **A** CT during arterial portography showed a tumor in the CP (*arrow*). The tumor with iodized oil accumulation that had previously been embolized was also seen in segment 4. **B** Arteriogram of the right hepatic artery showed that the caudate artery derived from the posterior segmental artery of

the right hepatic artery (*arrow*). The *arrowhead* shows a tumor stain. **C** The caudate artery was selected and embolized. The *arrow* showed a tumor stain. **D** CT obtained 1 week after TACE showed iodized oil accumulation in HCC in the CP

entire tumor portion after TACE, including those after six additional TACE sessions. Because multiple caudate arteries are frequently connected not only with each other but also with neighboring branches, iodized oil might also flow into the tumor through unidentified small caudate branches by way of these communications [16, 17].

In conclusion, the tumor-feeding caudate artery most frequently arose from the right hepatic artery, followed with almost equal frequency by the left hepatic artery, the anterior segmental artery of the right hepatic artery, and the posterior segmental artery of the right hepatic artery. HCCs located in the SP were fed by the caudate artery derived from both hepatic arteries (the ratio of right to left = 3:2); HCCs in the PC were also fed by both hepatic arteries (the ratio of right to left = 3:1); and HCCs in the CP were dominantly fed by the caudate artery derived from the right

hepatic artery. We consider that recognition of this tendency may be helpful to identify the tumor-feeding caudate artery on angiogram.

Conflict of Interest None.

References

1. Takayasu K, Muramatsu Y, Shima Y et al (1986) Clinical and radiologic features of hepatocellular carcinoma originating in the caudate lobe. *Cancer* 58:1557–1562
2. Tanaka S, Shimada M, Shirabe K et al (2005) Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. *Am J Surg* 190:451–455
3. Shimada M, Matsumata T, Maeda T et al (1994) Characteristics of hepatocellular carcinoma originating in the caudate lobe. *Hepatology* 19:911–915

4. Shibata T, Maetani Y, Ametani F et al (2002) Efficacy of non-surgical treatments for hepatocellular carcinoma in the caudate lobe. *Cardiovasc Intervent Radiol* 25:186–192
5. Seror O, Haddad D, N’Kontchou G et al (2005) Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. *J Vasc Interv Radiol* 16:981–990
6. Yamakado K, Nakatsuka A, Akeboshi M et al (2005) Percutaneous radiofrequency ablation for the treatment of liver neoplasms in the caudate lobe left of the vena cava: electrode placement through the left lobe of the liver under CT-fluoroscopic guidance. *Cardiovasc Intervent Radiol* 28:638–640
7. Miyayama S, Matsui O, Kameyama T et al (1990) Angiographic anatomy of arterial branches to the caudate lobe of the liver: with special reference to its effect on transarterial embolization of hepatocellular carcinoma. *Jpn J Clin Radiol* 35:353–359 (in Japanese)
8. Terayama N, Miyayama S, Tatsu H et al (1998) Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. *J Vasc Interv Radiol* 9:501–508
9. Yoon CJ, Chung JW, Cho BH et al (2008) Hepatocellular carcinoma in the caudate lobe of the liver: angiographic analysis of tumor-feeding arteries according to subsegmental location. *J Vasc Interv Radiol* 19:1543–1550
10. Mizumoto R, Suzuki H (1988) Surgical anatomy of the hepatic hilum with special reference to the caudate lobe. *World J Surg* 12:2–10
11. Suzuki H (1982) Correlation and anomalies of the vascular stricture in Glisson’s area around the hepatic hilum, from the standpoint of hepatobiliary surgery. *Arch Jpn Chir* 51:713–731 (in Japanese)
12. Miyayama S, Yamashiro M, Yoshie Y et al (2010) Hepatocellular carcinoma in the caudate lobe of the liver: variations of its feeding branches on arteriography. *Jpn J Radiol* 28:555–562
13. Kumon M (1985) Anatomy of the caudate lobe with special reference to portal vein and bile duct. *Acta Hepatol Jpn* 26:1193–1199 (in Japanese)
14. Matsui O, Kadoya M, Yoshikawa J et al (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. *Radiology* 188:79–83
15. Miyayama S, Matsui O, Yamashiro M et al (2007) Ultrasensitive transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. *J Vasc Interv Radiol* 18:365–376
16. Miyayama S, Yamashiro M, Okuda M et al (2010) Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 33:1168–1179
17. Miyayama S, Matsui O, Taki K et al (2005) Arterial blood supply to the posterior aspect of segment IV of the liver from the caudate branch: demonstration at CT after iodized oil injection. *Radiology* 237:1110–1114

Original Article

Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: Observation on CT during arterial portography

Shiro Miyayama,¹ Osamu Matsui,³ Yoh Zen,⁴ Masashi Yamashiro,¹ Yuki Hattori,¹ Nobuaki Orito,¹ Ken Matsui,¹ Kazunobu Tsuji,¹ Miki Yoshida¹ and Yoshiko Sudo²

Departments of ¹Diagnostic Radiology and ²Pathology, Fukuiken Saiseikai Hospital, Funabashi, Wadanaka-cho, Fukui, and ³Department of Radiology, Kanazawa University Graduate School of Medical Science, Takara-machi, Kanazawa, Japan; and ⁴Institute of Liver Studies, Kings College Hospital, Denmark Hill, London, UK

Aim: To analyze the clinical features of locally progressed hepatocellular carcinoma (HCC) supplied by portal blood (PB) after transcatheter arterial chemoembolization (TACE).

Methods: This cohort included 12 tumors (mean diameter \pm SD, 1.8 ± 0.8 cm) in 10 patients. PB supply to tumors was judged by CT during arterial portography (CTAP). Imaging data and the clinical course were retrospectively evaluated.

Results: Six tumors initially had a small tumor portion supplied by PB. In four tumors, TACE was incomplete because of technical problems. PB supply to recurrent tumors was demonstrated 7.3 ± 3.7 months after TACE. On follow-up arteriography, all embolized branches were occluded or severely attenuated. Four tumors showing a partial stain were treated by additional TACE ($n = 3$) or TACE plus radiofrequency (RF) ablation ($n = 1$), one without staining was treated by RF ablation, and seven were followed-up. All tumors progressed

except for one treated by RF ablation. On serial CTAP images, relatively large-diameter portal veins directly entered 11 tumors (91.7%) and connected with intratumoral vessels in nine (75%). During follow-up, partial arterial supply was demonstrated in two tumors and additional TACE was performed. Nine patients died after 31.4 ± 16.2 months due to tumor progression ($n = 8$), or hepatic failure ($n = 1$). One patient has survived for 53 months despite multiple tumors.

Conclusions: PB supply to locally progressed tumor after TACE became apparent on CTAP. Arterial damage by TACE, incomplete TACE, and preexisting tumor tissues supplied by PB may be the main causes.

Key words: CT during arteriography, hepatocellular carcinoma, portal blood supply, transcatheter arterial chemoembolization, tumor progression

INTRODUCTION

TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) is one of the effective therapeutic options for inoperable hepatocellular carcinoma (HCC).^{1–3} Because moderately to poorly-differentiated HCC (classical HCC) is exclusively supplied by arterial blood, embolization of the hepatic artery can be

theoretically expected to result in selective ischemic necrosis of the tumor tissue.¹

However, HCC frequently shows local progression after TACE. Portal blood supply to HCC lesions is considered as one of the important causes of tumor survival after TACE.^{4–6} To our knowledge, there are no reports concerning imaging findings of portal blood supply to locally progressed HCC after TACE except for a case report by Choi *et al.*⁶

We evaluated the portal blood supply to locally progressed HCC lesions using serial computed tomography (CT) during arterial portography (CTAP) performed just prior to each repeated TACE. Thus, the purpose of this study was to retrospectively analyze the imaging data and clinical course of locally progressed HCC lesions supplied by portal blood after TACE.

Correspondence: Dr Shiro Miyayama, Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan. Email: s-miyayama@fukuiken.saiseikai.or.jp

Received 14 March 2011; revision 24 April 2011; accepted 11 May 2011.

METHODS

Patient

THIS WAS A retrospective study in which existing imaging data were used with no effect on patient care; Institutional Review Board approval is not required at our institution for this type of study. Written informed consent was obtained from each patient before all TACE procedures.

Between September 2001 and December 2007, 277 patients were clinically diagnosed as having local progression of HCC after TACE. Imaging findings and clinical data of all patients were retrospectively analyzed. The diagnosis of local tumor progression was established when a viable tumor developed in or adjacent to the treated tumor with or without disappearance of iodized oil or when a tumor portion without iodized oil accumulation was enlarged on dynamic CT and/or magnetic resonance (MR) imaging. Portal blood supply to progressed HCC was judged as positive when all or the majority of the viable tumor showed isoattenuation or hyperattenuation compared to the background liver parenchyma on follow-up CTAP. We found 12 HCC lesions in 10 patients fed by portal blood during the same period. There were six men and four women, ranging in age from 49 to 82 years (mean values \pm standard deviation, 68.8 ± 9.8 years). All patients had liver cirrhosis related to hepatitis C virus. One to 13 TACE procedures (mean, 4.4 ± 3.5 times) had been performed during follow-up periods ranging from 5 to 100 months (mean, 41.3 ± 25.8 months) before disclosure of the portal blood supply to locally progressed HCC. One patient had undergone 4 TACE sessions on the right inferior phrenic artery (IPA) and another patient had undergone 5 TACE sessions on the right IPA and 2 sessions on the right renal capsular artery (RCA). Two patients had also undergone a single radiofrequency (RF) ablation therapy in addition to TACE at another site.

The diagnosis of local tumor progression was clinically established in seven tumors. Histopathological confirmation was obtained in five tumors (autopsy [$n = 3$], needle biopsy [$n = 2$]). Serum alpha-fetoprotein level (AFP) was elevated in eight patients (normal range < 20 ng/mL, range 132–16748, 132–400 [$n = 4$], 401–1000 [$n = 2$], > 1001 [$n = 2$]) and normal in one patient. Serum levels of AFP were not measured in one patient. Serum protein induced in vitamin K absence II (PIVKA-II) level was elevated in four patients (normal range < 40 mAU/mL [$\mu\text{g/L}$], range, 52–313, 52–200 [$n = 1$], 201–400 [$n = 3$]) and normal in five patients.

Serum levels of PIVKA-II were not measured in one patient. All patients showed elevated serum levels of either AFP or PIVKA-II.

CTAP protocol

During the TACE procedure, CTAP was routinely performed using a multidetector-row (MD) helical CT scanner (Aquilion-4, Aquilion-16, and Aquilion-64; Toshiba, Tokyo, Japan). Scanning in a craniocaudal direction (3-collimation, 3-mm-thick sections, 3-mm-reconstruction intervals, 135 kVp, and 200 mAs) was performed to cover the entire liver during a single breath hold. Seventy ml of diluted contrast material (35 mL of contrast material, 350 mg I/mL of iomeprol; Iomeron 350 [Ezai; Toyo, Japan] or 370 mg I/mL of iopamidol; Iopamiron 370 [Bayer, Osaka, Japan] in 35 mL of sterile saline) was injected using a power injector at a rate of 2.5 mL/s through a catheter placed in the superior mesenteric artery after administration of 2.5 μg of prostagrandin E1 (Liple; Tanabe Mitsubishi, Osaka, Japan). When replaced hepatic branches or arterial flow from the superior mesenteric artery toward the liver and tumor was demonstrated, the catheter tip was deeply advanced until these branches were avoided. Scanning was initiated 35 s after the injection of contrast material. The scan durations of a 4-, 16-, and 64-MDCT scanner for a scanned length of 20 cm were 7.3, 7.4, and 4.7 s, respectively.

Starting May 2006, CTAP studies were also performed using a cone-beam CT technique (XperCT; Philips Medical Systems; Best, The Netherlands) in three patients. Three-hundred and twelve projection images with X-ray parameters of 120 kV and 50–325 mAs were obtained with a 10.4-second acquisition and a 207-degree rotation of a 30×38 cm flat panel detector on the angiographic C-arm (Allura Xper FD20; Philips Medical Systems) around the patient. Forty mL of 370 mg I/mL of iopamidol was injected at a rate of 3 mL/s after administration of 2.5 μg of prostagrandin E1. Scanning was initiated 25 s after the injection of contrast material. Three-mm thickness images at optimal cross section were reconstructed using a workstation (Philips Medical Systems).

TACE procedure

All TACE procedures were performed by injecting either a mixture of 2–5 ml of iodized oil (Lipiodol; Andre Guerbet, Aulnay-sous-Bois, France) and anticancer drugs (10–30 mg of epirubicin [Farmorbicin; Pfizer, Tokyo, Japan] and 2–6 mg of mitomycin C [Mitomycin; Kyowa Hakkō Kirin, Tokyo, Japan]) followed by gelatin sponge

particles (Gelfoam; Upjohn, Kalamazoo, MI, USA, or Gelpart; Nippon Kayaku, Tokyo, Japan). After confirmation of tumor stain on arteriogram, TACE was performed through a 1.8-F tip (Carnelian PIXIE; Tokai Medical Products, Kasugai, Japan), 2-F tip (Progreat α; Terumo, Tokyo, Japan), or 2.4-F tip (Microferret; Cook, Bloomington, IN, USA) microcatheter navigated into the target vessel as distally as possible through a 4-F catheter. TACE through an extrahepatic collateral was also performed in the same fashion, if necessary. TACE procedures were ended when the tumor stain disappeared on arteriogram.

We named TACE performed just before disclosure of the portal blood supply to locally progressed tumors as “triggered TACE.”

Follow-up

In all patients, unenhanced CT was obtained 1 week after the TACE procedure in order to check for iodized oil accumulation in the target tumor. All patients were followed by dynamic CT or MR imaging every 2–4 months after triggered TACE. Angiography and CTAP were performed when tumor progression was suspected on follow-up images. When a locally progressed or newly developed tumor fed by arterial blood was demonstrated on angiography, additional TACE procedure, either through the hepatic artery and extrahepatic collaterals, was also performed. The locally progressed tumor without a tumor stain on angiography was either followed or treated by RF ablation, if possible.

RESULTS

CTAP and angiographic findings just before triggered TACE

THE FINDINGS ARE summarized in Table 1. The maximal tumor diameter ranged from 1–4 cm (mean, 1.8 ± 0.8 cm). Six tumors (50%) showed portal perfusion defect in the entire tumor (Figs 1,2). Six tumors (50%) showed a small tumor portion with decreased or preserved portal perfusion mainly at the periphery of the tumor (Fig. 3).

All tumors showed a tumor stain on arteriogram (Figs 1,2). TACE was performed at the subsegmental artery (*n* = 3), segmental artery (*n* = 6), of the hepatic artery. In the remaining tumor, TACE was performed at the right hepatic artery because of the presence of multicentric tumors and attenuation of the hepatic artery by previous TACE.

Table 1 Summary of each tumor and triggered TACE

Patient no./Age (year)/Sex	Tumor size (cm)	Tumor location†	Portal blood supply on CTAP	TACE level	Iodized oil accumulation
1/69/F	1.9	S8/4	None	Subsegmental	Dense, entire
2/61/M	2.6	S3	None	Subsegmental	Dense, entire
3/68/M	2	S8	Periphery	Segmental	Dense, hypervascular portion
	1.7	S8	None	Subsegmental	Sparse‡
4/82/F	1.6	S3	Periphery	Subsegmental	Dense, hypervascular portion
	4	S7	Periphery	Segmental, RRCA	Dense, hypervascular portion
5/49/M	1.7	S3	None	Subsegmental	Dense, partial defect‡
6/75/M	1.4	S8	Periphery	Subsegmental	Dense, hypervascular portion
7/65/M	2.1	S3	None	Subsegmental	Sparse‡
8/73/F	1	S3	None	Subsegmental	Dense, entire
9/81/M	1	S7	Periphery	Lobar	Sparse‡
10/65/F	1.3	S8	Periphery	Subsegmental	Dense, hypervascular portion

†Liver segment according to Couinaud classification.

‡Technical trouble during TACE was suspected.

CTAP, CT during arterial portography; RRCA, right renal capsular artery; TACE, transcatheter arterial chemoembolization.



Figure 1 Images in a 65-year-old man with a tumor fed by portal blood. (a) Arterial phase CT shows a hypervascular tumor in segment 3 of the liver (arrow). (b) CTAP shows portal perfusion defect in the tumor (arrow). (c) Arteriogram of the lateral segmental artery of the left hepatic artery shows a tumor stain (arrow) supplied by the ventral lateral segmental artery (A3) (arrowhead). (d) Selective arteriogram of A3 shows stasis of the tumor-feeding branch (arrow) and the tumor stain becomes faint (arrowhead). TACE was performed at this point. (e) CT obtained 1 week after TACE shows that iodized oil is sparsely accumulated in the tumor (arrow), although it is densely retained in A3 (arrowhead). Iodized oil in the tumor had washed out on follow-up CT obtained 6 months after TACE (not shown). (f) On CTAP obtained 7 months after TACE, the tumor has changed to isoattenuating and hyperattenuating. (g) On CTAP obtained 26 months after TACE, the tumor is enlarged and relatively large portal veins directly enter the tumor and connect with intratumoral vessels (arrows). In addition, the branch of the left hepatic vein runs adjacent to the tumor (arrowheads). On CT obtained 30 seconds after CTAP, the tumor appears as hypoattenuating. Iodized oil is still retained in A3 (arrow) suggesting complete occlusion of A3.




Figure 1 Continued.

The tumor-feeding right RCA was also embolized in one tumor. During catheter manipulation, the tumor stain became unclear in two tumors, probably because of a spasm or air embolism in the tumor-feeding branch (Fig. 1). TACE was performed in both tumors injecting a small amount of a mixture of iodized oil and anticancer drugs and gelatin sponge particles.

Outcomes of triggered TACE

Of six tumors with portal perfusion defect on CTAP, three tumors showed dense iodized oil accumulation in the entire tumor on CT obtained 1 week after TACE. Two tumors in which the stain was weakened during the catheter manipulation showed sparse iodized oil accumulation (Fig. 1). In the remaining tumor, iodized oil

was densely accumulated in most of the tumor except for a small part (Fig. 2).

Of six tumors showing a small portion with decreased or preserved portal perfusion on CTAP, five tumors showed dense iodized accumulation only in the tumor portion with portal perfusion defect on CT obtained 1 week after TACE (Fig. 3). In the remaining tumor, iodized oil was sparsely accumulated even in the tumor portion with portal perfusion defect.

In eight tumors, iodized oil was washed out and viable tumor was detected ($n = 2$) or gradually enlarged ($n = 6$) on follow-up CT obtained 1–10 months (mean, 5.5 ± 3.3 months) after TACE. In four tumors, viable tumor was demonstrated adjacent to densely accumulated iodized oil on follow-up CT obtained after 5–12 months (mean, 7.8 ± 3.4 months), including one




Figure 2 Images in a 49-year-old man with a tumor fed by portal blood. (a) Arterial phase CT shows a hypervascular tumor in segment 3 of the liver. (b) CTAP shows portal perfusion defect in the tumor. (c) Selective arteriogram of A3 shows a tumor stain. TACE was performed at this point. (d) CT obtained 1 week after TACE shows that iodized oil is not accumulated in the ventral portion of the tumor (arrow). (e) Delayed phase CT obtained 11 months after TACE shows a hypoattenuating tumor adjacent to the densely retained iodized oil (arrow). (f) CTAP obtained 12 months after TACE shows that the tumor is supplied by portal blood (arrow). (g) CTAP obtained 33 months after TACE shows that the tumor is enlarged and the portal vein directly enters the tumor.

tumor with incomplete iodized oil accumulation in a small hypervascular tumor portion (Figs 2,4).

CTAP findings at demonstration of the portal blood supply to locally progressed HCC

The findings are summarized in Table 2. Follow-up CTAP was performed 1–13 months (mean, 7.3 ± 3.7 months) after triggered TACE. The maximal tumor diameter supplied by portal blood ranged from 1.5–5.3 cm (mean, 2.5 ± 1.1 cm). In comparison with tumor diameter before triggered TACE, 10 tumors (83.3%) were enlarged and two (16.7%) were reduced in size.

One tumor (8.3%) showed hyperattenuation of the entire tumor (Fig. 2). Eleven tumors (91.7%) showed inhomogenous attenuation. Among these, five tumors (41.7%) showed hyperattenuation and isoattenuation (Figs 1,3), four (33.3%) showed hyperattenuation including a nodular hypoattenuating area, one (8.3%) showed a nodular hyperattenuation within the hypoattenuating area (Fig. 4), and one (8.3%) showed a rim-like and septum-like hyperattenuation around the hypoattenuating area.

Angiographic findings at demonstration of the portal blood supply to locally progressed HCC

Damage to the hepatic arterial branches by triggered TACE was observed in all 12 tumors. Of 11 tumors treated by TACE at a level more distal than the segmental artery, the embolized feeding branches were occluded ($n = 8$) or severely attenuated ($n = 3$) (Figs 4,5). Occlusion of tumor-feeding branches arising from the right RCA was also demonstrated in one tumor. In the remaining tumor treated by TACE of the right hepatic artery, severe attenuation of the right hepatic artery was observed.

In eight tumors without hypoattenuating areas ($n = 6$) or with a small hypoattenuating area ($n = 2$) on CTAP, there were no tumor stains demonstrated via the arterial side either through the hepatic and extrahepatic arteries.

CT during hepatic arteriography (CTHA) was performed in one of these tumors, and showed hepatic arterial perfusion defect not only in the locally progressed tumor but also in the surrounding liver parenchyma (Fig. 4). Four tumors with hypoattenuating areas on CTAP showed a partial tumor stain through the neighboring hepatic subsegmental artery.

Four tumors showing a partial tumor stain were treated by additional TACE. In one of these tumors, RF ablation for tumor portions supplied by portal blood was added after tumor biopsy using an 18 G needle (Monopty; Bard, Tempe, AZ, USA). In another tumor without obvious tumor stains, tumor biopsy and RF ablation were performed. The remaining seven tumors that did not show any tumor stains were followed without further treatment because of multiple other tumors ($n = 5$) or difficulty that prevented RF ablation ($n = 2$).

Outcomes and serial CTAP findings of each tumor

All patients were followed-up for 10–56 months (mean, 32.9 ± 16.0 months) after triggered TACE. One to 9 (mean, 4.9 ± 3.0) additional CTAP studies were performed in nine tumors, mainly to evaluate other tumors in the same patient. In all tumors but one, the tumor portion fed by portal blood was gradually enlarged. Only one tumor treated by RF ablation was well controlled during the 56-months follow-up. Serial CTAP images showed that relatively large-diameter portal veins directly entered 11 tumors (91.7%) and these connected with intranodular vessels in nine tumors (75%) (Figs 1,2,4,5).

In two tumors located in the lateral segment of the left lobe, CTAP obtained 26 months after triggered TACE showed that a branch of the left hepatic vein ran adjacent to the locally progressed tumor and was suspected being a tumor drainage vein (Figs 1,5). In two other tumors without tumor stains on arteriogram at disclosure of portal blood supply, partial arterial supply was demonstrated on follow-up arteriogram obtained after 33 and 44 months, respectively. Large vessels (probably




Figure 3 Images in a 61-year-old man with a tumor fed by portal blood. (a) CTAP shows a tumor with portal perfusion defect in segment 8 of the liver (arrow). A small tumor portion with preserved portal blood is also seen at the periphery of the tumor (arrowhead). TACE was performed at the anterior segmental artery of the right hepatic artery (not shown). (b) CT obtained 1 week after TACE shows dense iodized oil accumulation in almost all tumor portions with portal perfusion defect. However, the tumor progressed 7 months later (not shown). (c) On CTAP obtained 10 months after TACE, the tumor is enlarged and shows isoattenuation and hyperattenuation (arrow). Another tumor has also developed at another site (arrowhead). (d) CT obtained 30 seconds after CTAP shows that both tumors are demonstrated as hypoattenuating. (e) CTAP obtained 15 months after TACE shows that both tumors are enlarged. (f) On arteriography, the recurrent tumor does not show any tumor stains (not shown). The newly developed tumor is supplied by the phrenic branch of the right internal mammary artery. TACE was performed through the branch. (g) CTAP obtained 23 months after TACE shows that the tumor is enlarged and the embolized tumor is well controlled. (h) The patient died of tumor progression including cervical and mediastinal lymph node metastases 31 month after triggered TACE. The majority of the autopsy specimen of the tumor supplied by portal blood is diagnosed as moderately-differentiated HCC (hematoxylin and eosin staining, $\times 200$).

portal veins) were demonstrated within the tumor via the arterial side in both tumors and iodized oil flowed into these vessels during the additional TACE procedure (Fig. 5).

Nine patients died 5–26 months (mean, 31.4 ± 16.2 months) after triggered TACE. Eight of these patients died of tumor progression, including three with distant metastases [lung ($n = 1$), brain ($n = 1$), neck and mediastinal lymph nodes ($n = 1$)]. The remaining patient died of hepatic failure despite good tumor control by RF ablation. One patient has survived 53 months after triggered TACE with multiple viable tumors fed by arterial blood and portal blood in the liver.

Histopathological findings

Autopsy was performed in two patients 10 and 31 months after triggered TACE, respectively. Three tumors supplied by portal blood were confirmed in addition to several tumors supplied by arterial blood. Histologically, all three tumors were diagnosed as moderately-differentiated HCC including a small component of well-differentiated HCC (Fig. 3). Two other tumors in other two patients were also diagnosed as moderately-differentiated HCC by needle biopsy (Fig. 4). However, the origin of the intratumoral vessels could not be determined even in autopsy cases.

DISCUSSION

HCC FREQUENTLY ARISES by multistep sequential development from a dysplastic nodule, a dysplastic nodule with malignant foci, a well-differentiated HCC nodule to definite classical HCC in cirrhotic liver.^{7,8} During the multistep process of hepatocarcinogenesis, the source of vascular supply in a hepatic

nodule switches from the portal vein to the hepatic artery. Intranodular portal blood flow tends to decrease as the grade of malignancy increases, and classic HCC is mainly supplied by arterial blood.^{7–10} Early-stage HCC usually has well-differentiated tumor portions fed by portal blood,^{8,9} and tumor cells of capsular invasion are also supplied by both arterial and portal blood even in classical HCC.¹¹

Portal blood supply to HCC after TACE is thought to be one of the causes of tumor survival.^{4–6} Ekelund *et al.* investigated the blood supply in rats with experimental liver tumors after arterial embolization with gelatin sponge powder or ethanol.⁴ They found that portal blood supply to tumors clearly increased after arterial embolization. Using an immunohistochemical method, Goseki *et al.* reported the increase of residual tumor cells supplied by portal blood after TACE.⁵ Choi *et al.* reported that the nourishing vessels of tumors treated by repeated TACE changed from the hepatic artery to the portal vein.⁶ Sufficient therapeutic effects of combined arterial and portal embolization compared to those of conventional arterial side TACE as well as excellent local control effects in tumors with marked portal vein visualization by iodized oil during TACE may support these hypotheses.^{11–16} Clinically, however, portal blood supply to locally progressed HCCs has not received much attention.

When the tumor-feeding branch is occluded by TACE, a survived tumor may receive arterial blood from two other possible pathways; intact neighboring hepatic arterial branches and extrahepatic collaterals.^{17,18} When the neighboring hepatic branches are occluded and extrahepatic arteries cannot reach the tumor because of tumor location or interruption of collaterals by previous TACE, the survived tumor may not be able to receive arterial blood. Under such circumstances, the pro-




Figure 4 Images in a 75-year-old man with a tumor fed by portal blood. (a) Unenhanced CT obtained 13 months after TACE shows a hypoattenuating mass near the iodized oil accumulated tumor in segment 8 of the liver (arrow). (b) Celiac arteriogram shows that the anterior superior subsegmental artery of the liver is severely attenuated by the previous TACE procedure. There are no tumor stains corresponding to the recurrent tumor. A newly developed tumor is seen at another site (arrowhead), and TACE was subsequently performed for this tumor (not shown). (c) CTHA shows arterial perfusion defect including the tumor. (d) On CTAP, the tumor shows hypoattenuation and hyperattenuation (mosaic-like enhancement). The portal veins directly enter the tumor (arrow). (e) Diagnosis of moderately-differentiated HCC is established by needle biopsy specimen (hematoxylin and eosin staining, x 200). RF ablation was performed for this tumor.

gressed tumor may mainly be nourished by portal blood and the hemodynamics may become apparent on imaging.

The present study included two different types of tumors. According to CTAP and angiographic findings,

50% of tumors were supplied by arterial blood alone before TACE. In such tumors, tumor blood usually enters via the hepatic artery and drains into the portal venules connecting with tumor sinusoids near the tumor capsule.^{9,19} Tochio *et al.* discovered patent portal

Table 2 Outcomes of each tumor

Patient no./Age (y)/Sex	Size of recurrent tumor (cm)	Duration between TACE and tumor recurrence (mo)	CTAP findings	Damage of embolized arteries	Angiographic findings	Histological findings	Additional treatment	Outcomes
1/69/F	1.6	5	Hypo and hyper	Occluded	Stain, partial	Mod	TACE + RFA	Dead, 47 mo (T)
2/61/M	2.8	10	Iso and hyper	Occluded	No stains	Mod > Well	Follow-up	Dead, 31 mo (T)
3/68/M	2.6	9	Hypo and hyper	Occluded	Stain, partial	Mod > Well	TACE	
	1.8	1	Hypo and hyper	Attenuated	Spain, partial	None	TACE	Dead, 14 mo (T)
4/82/F	1.9	2	Iso and hyper	Occluded	No stains	None	Follow-up	
	5.3	8	Hypo and hyper	Occluded	Stain, partial	None	TACE	Dead, 21 mo (T)
5/49/M	2.3	9	Hyper	Occluded	No stains	None	Follow-up†	Dead, 38 mo (T)
6/75/M	3.2	12	Hypo and hyper	Attenuated	No stains	Mod	RFA	Dead, 56 mo (H)
7/65/M	1.5	6	Iso and hyper	Occluded	No stains	None	Follow-up	Dead, 46 mo (T)
8/73/F	1.6	10	Iso and hyper	Occluded	No stains	None	Follow-up‡	Alive, 53 mo
9/81/M	2.1	4	Hypo and hyper	Attenuated	No stains	Mod	Follow-up	Dead, 10 mo (T)
10/65/F	2.8	5	Iso and hyper	Attenuated	No stains	None	Follow-up	Dead, 20 mo (T)

†Additional TACE was performed 44 months after disclosure of the portal blood supply to the recurrent tumor.

‡Additional TACE was performed 33 months after disclosure of the portal blood supply to the recurrent tumor.

CTAP, CT during arterial portography; (H), hepatic failure; Hyper, hyperattenuation; Hypo, hypoattenuation; Iso, isoattenuation; Mod, moderately differentiated; RFA, radiofrequency ablation; (T), tumor progression; TACE, transcatheter arterial chemoembolization; Well, well-differentiated.

branches at the periphery or septum of classical HCC nodules.²⁰ It is speculated that blood flow in such remnant portal veins within HCC changes to regurgitating draining flow as a result of markedly increased arterial flow induced by intranodular neovascularization. When the increased arterial flow is blocked by TACE, flow in the remnant portal veins may reverse directions. If the afferent arteries are completely occluded while tumor sinusoids persist due to incomplete TACE, these portal veins may switch to feeding vessels of the surviving HCC tissues. Entirely or partially incomplete iodized oil accumulation despite hypervascularity was found in four tumors (33%) in the present series, which might support this hypothesis. On the other hand, 50% of the tumors in this study initially showed a small tumor portion supplied by portal blood. In such tumors, the tumor tissues originally supplied by portal blood might also survive after TACE.²¹ However, the combination of CTAP and angiography might not be sensitive to the detection of a small portion of tumor tissue supplied by portal blood at the periphery of the tumor. In the present study, two tumors supplied by portal blood developed adjacent to the tumor showing dense iodized oil accumulation. This suggested that both tumors initially had a small tumor portion supplied by portal blood. It might be occasionally difficult to demonstrate such a tumor tissue without CTHA study.

Ultraslective TACE has strong therapeutic effects on small HCC lesions,^{14,15} even on some early-stage tumors with hypovascular tumor portions.²² However, far advancement of a microcatheter carries the risks of incomplete TACE due to vascular spasm, air embolism, or vessel injury, in addition to missing small feeders.¹⁴ Technical problems, such as complete occlusion of tumor-feeding artery and incomplete occlusion of tumor sinusoids, may exaggerate the portal blood supply to survived tumors. Occlusion or severe attenuation of the embolized arterial branches on follow-up angiograms might support this hypothesis. In two tumors, partial tumor stain was demonstrated again via the arterial side on follow-up arteriograms, obtained 33 and 44 months later, respectively. In both tumors, arteriogram showed large vessels, probably portal veins, in the tumor. We speculate that some tumors supplied by portal blood may eventually be partially supplied by arterial blood when the hepatic or extrahepatic arteries are sufficiently restored to feed a progressed tumor. In addition, the large vessels demonstrated on arteriograms may correspond to intratumoral vessels on CTAP, and these may be demonstrated through arteriportal




Figure 5 Images in a 73-year-old woman with a tumor fed by portal blood. (a) Arterial phase CT obtained 44 months after triggered TACE shows a large tumor in the left lobe of the liver. Iodized oil in the tumor is also seen (arrow). (b) CTAP obtained 44 months after triggered TACE using cone-beam CT technique shows that the tumor is mainly supplied by portal blood. (c) On maximum intensity projection image of oblique coronal view of CTAP using cone-beam CT technique, a large portal vein is observed directly entering the tumor (arrow). The branch of the left hepatic vein also runs adjacent to the tumor (arrowhead). Artifacts from metallic coils are also seen. (d) Left hepatic arteriogram shows a partial tumor stain supplied by a branch directly arising from the proximal portion. The large vessel (probably the portal vein) is seen in the tumor (arrow). The lateral segmental artery of the left hepatic artery is severely attenuated by previous TACE sessions. (e) During TACE, large vessels are demonstrated in the tumor via the arterial side. To date, the tumor has gradually enlarged despite additional TACE (not shown).

connections via the arterial side, that was confirmed by experimental hepatic metastatic nodules.²³

In approximately 92% of our tumors, CTAP clearly demonstrated large-diameter portal veins directly entering into the tumor, these were suspected of being remnant portal veins. Although dilated intratumoral vessels were also seen in 75% of tumors, it was uncertain whether these intratumoral vessels were dilated original tumor sinusoids or remnant portal veins, even on autopsy specimens. There is another question of where tumor blood entering via the portal vein drains. In two tumors, it was suggested that the hepatic veins provided as tumor drainage. We speculate that the drainage vessels may also change from peritumoral portal veins to peritumoral hepatic veins when the nourishing vessels switch from the arteries to portal veins, although intratumoral hepatic veins are usually occluded early during hepatocarcinogenesis.²⁴ Intact intratumoral or peritumoral hepatic veins may be necessary so that the tumor would maintain the portal blood supply. Thus, we speculate that the survived tumor can progress while continuously receiving portal blood when the afferent artery is completely interrupted at the early step of carcinogenesis.

Kudo and Hirano *et al.* reported an atypical large well-differentiated HCC mainly supplied by portal blood.^{25,26} There are several differences between the tumors in their series and these in ours. First, the entire or the major areas of our tumors were fed by arterial blood before TACE. Second, most our tumors showed inhomogenous enhancement by portal blood, whereas atypical large well-differentiated HCCs usually show almost uniform enhancement on CTAP.^{25,26} Finally, all our tumors were histologically proven to be moderately-differentiated HCC.

There are several limitations in the present study. First, histological confirmation of HCC was not obtained in any tumors before TACE. However, we consider that advances in imaging modalities can facilitate establishment of the diagnosis of HCC without biopsy. Second, histopathologic confirmation of HCC was only obtained in 42% of locally progressed tumors supplied by portal blood. However, elevation of serum tumor marker levels and tumor progression during the follow-up period might establish the diagnosis of locally progressed HCC. Third, CTHA was not performed in any patient before TACE. This might be a significant limitation to detect a hypovascular tumor portion supplied by portal blood mainly located at the periphery of the tumor. Therefore, the actual incidence of tumor portions being supplied by portal blood might

have been underestimated in our cases. Finally, locally progressed tumors that were obviously fed by portal blood were selected in the present study. Faint portal blood supply at the periphery of a survived tumor may not be rare but cannot be detected even by a combination of CTAP and CTHA.

In conclusion, portal blood supply to HCC lesions after TACE may cause local tumor progression. CTAP can clearly depict relatively large-diameter portal veins entering the tumor and connecting with intranodular vessels. Incomplete TACE and/or the presence of tumor tissues initially supplied by portal blood are thought to be the main causes of the portal blood supply to locally progressed HCC. For such tumors, TACE may have limited therapeutic effects and RF ablation may be effective. Interventional radiologists and physicians should become well aware of such unusual tumors.

REFERENCES

- 1 Yamada R, Sato M, Kawabata M *et al.* Hepatic artery embolization in 120 patients with unresectable hepatoma. *Radiology* 1983; 148: 397–401.
- 2 Uchida H, Ohishi H, Matsuo N *et al.* Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 1990; 13: 140–5.
- 3 Matsui O, Kadoya M, Yoshikawa J *et al.* Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. *Radiology* 1993; 188: 79–83.
- 4 Ekelund L, Lin G, Jeppsson B. Blood supply of experimental liver tumors after intraarterial embolization with Gelfoam powder and absolute ethanol. *Cardiovasc Intervent Radiol* 1984; 7: 234–9.
- 5 Goseki N, Nosaka T, Endo M, Koike M. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. *Cancer* 1995; 76: 736–42.
- 6 Choi SH, Chung JW, Lee HS. Hepatocellular carcinoma supplied by portal flow after repeated transcatheter arterial chemoembolization. *AJR Am J Roentgenol* 2003; 181: 889–90.
- 7 Hayashi M, Matsui O, Ueda K *et al.* Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. *AJR Am J Roentgenol* 1999; 172: 969–76.
- 8 Matsui O, Ueda K, Kobayashi S *et al.* Intra- and perinodular hemodynamics of hepatocellular carcinoma: CT observation during intra-arterial contrast injection. *Abdom Imaging* 2002; 27: 147–56.
- 9 Ueda K, Terada T, Nakanuma Y, Matsui O. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular